Additionally, we provide data for a novel role of the p53 status in glioma cell lines as a determining factor for synergistic effects of ATRi plus olaparib as well as ATRi plus temozolomide in the absence of MGMT. This evidence concerns the gene TP53 and central nervous system cancer.